Global SPECT and PET Diagnosis Radiopharmaceuticals Market Growth 2026-2032
The global SPECT and PET Diagnosis Radiopharmaceuticals market size is predicted to grow from US$ 5611 million in 2025 to US$ 9022 million in 2032; it is expected to grow at a CAGR of 7.2% from 2026 to 2032.
SPECT and PET diagnosis radiopharmaceuticals refer to nuclear medicine diagnostic agents used in Single Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET) imaging. These agents are typically formed by combining radioactive isotopes with biologically active molecules such as small compounds, peptides, or antibodies through chemical or biological conjugation. After administration, the radiopharmaceutical participates in specific physiological or biochemical processes in the body and emits detectable radiation signals that can be captured by imaging systems, enabling visualization of organ function, metabolic activity, and molecular-level biological changes. SPECT and PET radiopharmaceuticals are widely used in oncology diagnostics, cardiovascular evaluation, neurological disease detection, and the localization of infection or inflammation. They play a fundamental role in molecular imaging and precision medicine. With the development of targeted molecular probes and new radionuclides, these agents are evolving from traditional functional imaging toward early disease detection and molecular mechanism diagnostics, becoming an essential component of modern medical imaging systems.In 2025, global SPECT and PET diagnosis radiopharmaceutical production reached approximately X156.28 million Units and price is about 36.7USD/Unit.The average gross profit margin of this product is 65%.
With the rapid advancement of precision medicine and molecular imaging technologies, SPECT and PET diagnostic radiopharmaceuticals are becoming increasingly important in modern healthcare systems. The growing need for early diagnosis of cancer, neurological disorders, and cardiovascular diseases has significantly expanded the role of molecular imaging in clinical practice. Continuous development of targeted molecular probes and new radionuclides enables radiopharmaceuticals to more accurately reflect metabolic processes and molecular activities in the body, improving diagnostic sensitivity and specificity. In addition, the expansion of nuclear medicine centers, upgrades in medical imaging infrastructure, and the integration of diagnostic and therapeutic approaches are further accelerating the clinical adoption of SPECT and PET diagnostic agents.
Despite their high clinical value and technological sophistication, SPECT and PET diagnostic radiopharmaceuticals face several industry challenges. The development, production, and transportation of radioactive drugs require strict regulatory compliance related to nuclear safety and pharmaceutical quality control, which imposes high operational standards on manufacturers. Some critical radioisotopes have short half-lives, requiring reliable isotope supply systems and highly efficient logistics networks, which adds complexity to the supply chain. Additionally, the shortage of specialized nuclear medicine professionals and the uneven technical capabilities of medical institutions may affect the broader adoption and commercialization of these diagnostic agents.
In downstream medical applications, the role of SPECT and PET radiopharmaceuticals is gradually shifting from traditional organ function imaging toward molecular-level disease detection. PET imaging has become increasingly important for tumor staging, therapy response evaluation, and recurrence monitoring. Meanwhile, demand is growing in areas such as neurodegenerative diseases, inflammatory disorders, and immune-related conditions. With the development of personalized medicine, targeted diagnostic probes designed for specific biological markers are expanding, creating closer synergy between diagnostic imaging and targeted therapy. In the future, theranostic radiopharmaceuticals and companion diagnostics are expected to become key growth areas.
The upstream supply chain of SPECT and PET diagnostic radiopharmaceuticals mainly includes radioactive isotopes, chemical precursor molecules, and radiolabeling reagents. Commonly used radionuclides include technetium isotopes, fluorine isotopes, and iodine isotopes, which are typically produced through nuclear reactors or medical cyclotrons. Chemical precursor molecules serve as carriers that bind to radioactive isotopes to form specific molecular probes, and their structural design directly influences targeting capability and imaging performance. In addition, stable radiolabeling technologies and high-purity reagents are essential for ensuring the safety and imaging quality of these drugs. With the continuous evolution of nuclear medicine technologies, upstream materials are moving toward higher purity, better stability, and enhanced targeting efficiency.
LP Information, Inc. (LPI) ' newest research report, the ?SPECT and PET Diagnosis Radiopharmaceuticals Industry Forecast? looks at past sales and reviews total world SPECT and PET Diagnosis Radiopharmaceuticals sales in 2025, providing a comprehensive analysis by region and market sector of projected SPECT and PET Diagnosis Radiopharmaceuticals sales for 2026 through 2032. With SPECT and PET Diagnosis Radiopharmaceuticals sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world SPECT and PET Diagnosis Radiopharmaceuticals industry.
This Insight Report provides a comprehensive analysis of the global SPECT and PET Diagnosis Radiopharmaceuticals landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on SPECT and PET Diagnosis Radiopharmaceuticals portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global SPECT and PET Diagnosis Radiopharmaceuticals market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for SPECT and PET Diagnosis Radiopharmaceuticals and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global SPECT and PET Diagnosis Radiopharmaceuticals.
This report presents a comprehensive overview, market shares, and growth opportunities of SPECT and PET Diagnosis Radiopharmaceuticals market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
SPECT and PET diagnosis radiopharmaceuticals refer to nuclear medicine diagnostic agents used in Single Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET) imaging. These agents are typically formed by combining radioactive isotopes with biologically active molecules such as small compounds, peptides, or antibodies through chemical or biological conjugation. After administration, the radiopharmaceutical participates in specific physiological or biochemical processes in the body and emits detectable radiation signals that can be captured by imaging systems, enabling visualization of organ function, metabolic activity, and molecular-level biological changes. SPECT and PET radiopharmaceuticals are widely used in oncology diagnostics, cardiovascular evaluation, neurological disease detection, and the localization of infection or inflammation. They play a fundamental role in molecular imaging and precision medicine. With the development of targeted molecular probes and new radionuclides, these agents are evolving from traditional functional imaging toward early disease detection and molecular mechanism diagnostics, becoming an essential component of modern medical imaging systems.In 2025, global SPECT and PET diagnosis radiopharmaceutical production reached approximately X156.28 million Units and price is about 36.7USD/Unit.The average gross profit margin of this product is 65%.
With the rapid advancement of precision medicine and molecular imaging technologies, SPECT and PET diagnostic radiopharmaceuticals are becoming increasingly important in modern healthcare systems. The growing need for early diagnosis of cancer, neurological disorders, and cardiovascular diseases has significantly expanded the role of molecular imaging in clinical practice. Continuous development of targeted molecular probes and new radionuclides enables radiopharmaceuticals to more accurately reflect metabolic processes and molecular activities in the body, improving diagnostic sensitivity and specificity. In addition, the expansion of nuclear medicine centers, upgrades in medical imaging infrastructure, and the integration of diagnostic and therapeutic approaches are further accelerating the clinical adoption of SPECT and PET diagnostic agents.
Despite their high clinical value and technological sophistication, SPECT and PET diagnostic radiopharmaceuticals face several industry challenges. The development, production, and transportation of radioactive drugs require strict regulatory compliance related to nuclear safety and pharmaceutical quality control, which imposes high operational standards on manufacturers. Some critical radioisotopes have short half-lives, requiring reliable isotope supply systems and highly efficient logistics networks, which adds complexity to the supply chain. Additionally, the shortage of specialized nuclear medicine professionals and the uneven technical capabilities of medical institutions may affect the broader adoption and commercialization of these diagnostic agents.
In downstream medical applications, the role of SPECT and PET radiopharmaceuticals is gradually shifting from traditional organ function imaging toward molecular-level disease detection. PET imaging has become increasingly important for tumor staging, therapy response evaluation, and recurrence monitoring. Meanwhile, demand is growing in areas such as neurodegenerative diseases, inflammatory disorders, and immune-related conditions. With the development of personalized medicine, targeted diagnostic probes designed for specific biological markers are expanding, creating closer synergy between diagnostic imaging and targeted therapy. In the future, theranostic radiopharmaceuticals and companion diagnostics are expected to become key growth areas.
The upstream supply chain of SPECT and PET diagnostic radiopharmaceuticals mainly includes radioactive isotopes, chemical precursor molecules, and radiolabeling reagents. Commonly used radionuclides include technetium isotopes, fluorine isotopes, and iodine isotopes, which are typically produced through nuclear reactors or medical cyclotrons. Chemical precursor molecules serve as carriers that bind to radioactive isotopes to form specific molecular probes, and their structural design directly influences targeting capability and imaging performance. In addition, stable radiolabeling technologies and high-purity reagents are essential for ensuring the safety and imaging quality of these drugs. With the continuous evolution of nuclear medicine technologies, upstream materials are moving toward higher purity, better stability, and enhanced targeting efficiency.
LP Information, Inc. (LPI) ' newest research report, the ?SPECT and PET Diagnosis Radiopharmaceuticals Industry Forecast? looks at past sales and reviews total world SPECT and PET Diagnosis Radiopharmaceuticals sales in 2025, providing a comprehensive analysis by region and market sector of projected SPECT and PET Diagnosis Radiopharmaceuticals sales for 2026 through 2032. With SPECT and PET Diagnosis Radiopharmaceuticals sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world SPECT and PET Diagnosis Radiopharmaceuticals industry.
This Insight Report provides a comprehensive analysis of the global SPECT and PET Diagnosis Radiopharmaceuticals landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on SPECT and PET Diagnosis Radiopharmaceuticals portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global SPECT and PET Diagnosis Radiopharmaceuticals market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for SPECT and PET Diagnosis Radiopharmaceuticals and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global SPECT and PET Diagnosis Radiopharmaceuticals.
This report presents a comprehensive overview, market shares, and growth opportunities of SPECT and PET Diagnosis Radiopharmaceuticals market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Technetium 99
- Fluorine 18
- Other
- PET Imaging
- SPECT Imaging
- Hospitals
- Imaging Centers
- Other
- Oncology
- Cardiology
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Cardinal Health
- GE Healthcare
- Jubilant Pharma
- Novartis
- Curium Pharma
- SIEMENS
- Lantheus
- Bracco Imaging
- Eli Lilly
- China Isotope & Radiation
- Dongcheng
- What is the 10-year outlook for the global SPECT and PET Diagnosis Radiopharmaceuticals market?
- What factors are driving SPECT and PET Diagnosis Radiopharmaceuticals market growth, globally and by region?
- Which technologies are poised for the fastest growth by market and region?
- How do SPECT and PET Diagnosis Radiopharmaceuticals market opportunities vary by end market size?
- How does SPECT and PET Diagnosis Radiopharmaceuticals break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global SPECT and PET Diagnosis Radiopharmaceuticals Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for SPECT and PET Diagnosis Radiopharmaceuticals by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for SPECT and PET Diagnosis Radiopharmaceuticals by Country/Region, 2021, 2025 & 2032
2.2 SPECT and PET Diagnosis Radiopharmaceuticals Segment by Type
2.2.1 Technetium
2.2.2 Fluorine
2.2.3 Other
2.2.4 SPECT and PET Diagnosis Radiopharmaceuticals Sales by Type
2.2.4.1 Global SPECT and PET Diagnosis Radiopharmaceuticals Sales Market Share by Type (2021-2026)
2.2.4.2 Global SPECT and PET Diagnosis Radiopharmaceuticals Revenue and Market Share by Type (2021-2026)
2.2.4.3 Global SPECT and PET Diagnosis Radiopharmaceuticals Sale Price by Type (2021-2026)
2.3 SPECT and PET Diagnosis Radiopharmaceuticals Segment by Imaging Modality
2.3.1 PET Imaging
2.3.2 SPECT Imaging
2.3.3 SPECT and PET Diagnosis Radiopharmaceuticals Sales by Imaging Modality
2.3.3.1 Global SPECT and PET Diagnosis Radiopharmaceuticals Sales Market Share by Imaging Modality (2021-2026)
2.3.3.2 Global SPECT and PET Diagnosis Radiopharmaceuticals Revenue and Market Share by Imaging Modality (2021-2026)
2.3.3.3 Global SPECT and PET Diagnosis Radiopharmaceuticals Sale Price by Imaging Modality (2021-2026)
2.4 SPECT and PET Diagnosis Radiopharmaceuticals Segment by End User
2.4.1 Hospitals
2.4.2 Imaging Centers
2.4.3 Other
2.4.4 SPECT and PET Diagnosis Radiopharmaceuticals Sales by End User
2.4.4.1 Global SPECT and PET Diagnosis Radiopharmaceuticals Sales Market Share by End User (2021-2026)
2.4.4.2 Global SPECT and PET Diagnosis Radiopharmaceuticals Revenue and Market Share by End User (2021-2026)
2.4.4.3 Global SPECT and PET Diagnosis Radiopharmaceuticals Sale Price by End User (2021-2026)
2.5 SPECT and PET Diagnosis Radiopharmaceuticals Segment by Application
2.5.1 Oncology
2.5.2 Cardiology
2.5.3 Other
2.5.4 SPECT and PET Diagnosis Radiopharmaceuticals Sales by Application
2.5.4.1 Global SPECT and PET Diagnosis Radiopharmaceuticals Sale Market Share by Application (2021-2026)
2.5.4.2 Global SPECT and PET Diagnosis Radiopharmaceuticals Revenue and Market Share by Application (2021-2026)
2.5.4.3 Global SPECT and PET Diagnosis Radiopharmaceuticals Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global SPECT and PET Diagnosis Radiopharmaceuticals Breakdown Data by Company
3.1.1 Global SPECT and PET Diagnosis Radiopharmaceuticals Annual Sales by Company (2021-2026)
3.1.2 Global SPECT and PET Diagnosis Radiopharmaceuticals Sales Market Share by Company (2021-2026)
3.2 Global SPECT and PET Diagnosis Radiopharmaceuticals Annual Revenue by Company (2021-2026)
3.2.1 Global SPECT and PET Diagnosis Radiopharmaceuticals Revenue by Company (2021-2026)
3.2.2 Global SPECT and PET Diagnosis Radiopharmaceuticals Revenue Market Share by Company (2021-2026)
3.3 Global SPECT and PET Diagnosis Radiopharmaceuticals Sale Price by Company
3.4 Key Manufacturers SPECT and PET Diagnosis Radiopharmaceuticals Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers SPECT and PET Diagnosis Radiopharmaceuticals Product Location Distribution
3.4.2 Players SPECT and PET Diagnosis Radiopharmaceuticals Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR SPECT AND PET DIAGNOSIS RADIOPHARMACEUTICALS BY GEOGRAPHIC REGION
4.1 World Historic SPECT and PET Diagnosis Radiopharmaceuticals Market Size by Geographic Region (2021-2026)
4.1.1 Global SPECT and PET Diagnosis Radiopharmaceuticals Annual Sales by Geographic Region (2021-2026)
4.1.2 Global SPECT and PET Diagnosis Radiopharmaceuticals Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic SPECT and PET Diagnosis Radiopharmaceuticals Market Size by Country/Region (2021-2026)
4.2.1 Global SPECT and PET Diagnosis Radiopharmaceuticals Annual Sales by Country/Region (2021-2026)
4.2.2 Global SPECT and PET Diagnosis Radiopharmaceuticals Annual Revenue by Country/Region (2021-2026)
4.3 Americas SPECT and PET Diagnosis Radiopharmaceuticals Sales Growth
4.4 APAC SPECT and PET Diagnosis Radiopharmaceuticals Sales Growth
4.5 Europe SPECT and PET Diagnosis Radiopharmaceuticals Sales Growth
4.6 Middle East & Africa SPECT and PET Diagnosis Radiopharmaceuticals Sales Growth
5 AMERICAS
5.1 Americas SPECT and PET Diagnosis Radiopharmaceuticals Sales by Country
5.1.1 Americas SPECT and PET Diagnosis Radiopharmaceuticals Sales by Country (2021-2026)
5.1.2 Americas SPECT and PET Diagnosis Radiopharmaceuticals Revenue by Country (2021-2026)
5.2 Americas SPECT and PET Diagnosis Radiopharmaceuticals Sales by Type (2021-2026)
5.3 Americas SPECT and PET Diagnosis Radiopharmaceuticals Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC SPECT and PET Diagnosis Radiopharmaceuticals Sales by Region
6.1.1 APAC SPECT and PET Diagnosis Radiopharmaceuticals Sales by Region (2021-2026)
6.1.2 APAC SPECT and PET Diagnosis Radiopharmaceuticals Revenue by Region (2021-2026)
6.2 APAC SPECT and PET Diagnosis Radiopharmaceuticals Sales by Type (2021-2026)
6.3 APAC SPECT and PET Diagnosis Radiopharmaceuticals Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe SPECT and PET Diagnosis Radiopharmaceuticals by Country
7.1.1 Europe SPECT and PET Diagnosis Radiopharmaceuticals Sales by Country (2021-2026)
7.1.2 Europe SPECT and PET Diagnosis Radiopharmaceuticals Revenue by Country (2021-2026)
7.2 Europe SPECT and PET Diagnosis Radiopharmaceuticals Sales by Type (2021-2026)
7.3 Europe SPECT and PET Diagnosis Radiopharmaceuticals Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa SPECT and PET Diagnosis Radiopharmaceuticals by Country
8.1.1 Middle East & Africa SPECT and PET Diagnosis Radiopharmaceuticals Sales by Country (2021-2026)
8.1.2 Middle East & Africa SPECT and PET Diagnosis Radiopharmaceuticals Revenue by Country (2021-2026)
8.2 Middle East & Africa SPECT and PET Diagnosis Radiopharmaceuticals Sales by Type (2021-2026)
8.3 Middle East & Africa SPECT and PET Diagnosis Radiopharmaceuticals Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of SPECT and PET Diagnosis Radiopharmaceuticals
10.3 Manufacturing Process Analysis of SPECT and PET Diagnosis Radiopharmaceuticals
10.4 Industry Chain Structure of SPECT and PET Diagnosis Radiopharmaceuticals
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 SPECT and PET Diagnosis Radiopharmaceuticals Distributors
11.3 SPECT and PET Diagnosis Radiopharmaceuticals Customer
12 WORLD FORECAST REVIEW FOR SPECT AND PET DIAGNOSIS RADIOPHARMACEUTICALS BY GEOGRAPHIC REGION
12.1 Global SPECT and PET Diagnosis Radiopharmaceuticals Market Size Forecast by Region
12.1.1 Global SPECT and PET Diagnosis Radiopharmaceuticals Forecast by Region (2027-2032)
12.1.2 Global SPECT and PET Diagnosis Radiopharmaceuticals Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global SPECT and PET Diagnosis Radiopharmaceuticals Forecast by Type (2027-2032)
12.7 Global SPECT and PET Diagnosis Radiopharmaceuticals Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Cardinal Health
13.1.1 Cardinal Health Company Information
13.1.2 Cardinal Health SPECT and PET Diagnosis Radiopharmaceuticals Product Portfolios and Specifications
13.1.3 Cardinal Health SPECT and PET Diagnosis Radiopharmaceuticals Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Cardinal Health Main Business Overview
13.1.5 Cardinal Health Latest Developments
13.2 GE Healthcare
13.2.1 GE Healthcare Company Information
13.2.2 GE Healthcare SPECT and PET Diagnosis Radiopharmaceuticals Product Portfolios and Specifications
13.2.3 GE Healthcare SPECT and PET Diagnosis Radiopharmaceuticals Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 GE Healthcare Main Business Overview
13.2.5 GE Healthcare Latest Developments
13.3 Jubilant Pharma
13.3.1 Jubilant Pharma Company Information
13.3.2 Jubilant Pharma SPECT and PET Diagnosis Radiopharmaceuticals Product Portfolios and Specifications
13.3.3 Jubilant Pharma SPECT and PET Diagnosis Radiopharmaceuticals Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Jubilant Pharma Main Business Overview
13.3.5 Jubilant Pharma Latest Developments
13.4 Novartis
13.4.1 Novartis Company Information
13.4.2 Novartis SPECT and PET Diagnosis Radiopharmaceuticals Product Portfolios and Specifications
13.4.3 Novartis SPECT and PET Diagnosis Radiopharmaceuticals Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Novartis Main Business Overview
13.4.5 Novartis Latest Developments
13.5 Curium Pharma
13.5.1 Curium Pharma Company Information
13.5.2 Curium Pharma SPECT and PET Diagnosis Radiopharmaceuticals Product Portfolios and Specifications
13.5.3 Curium Pharma SPECT and PET Diagnosis Radiopharmaceuticals Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Curium Pharma Main Business Overview
13.5.5 Curium Pharma Latest Developments
13.6 SIEMENS
13.6.1 SIEMENS Company Information
13.6.2 SIEMENS SPECT and PET Diagnosis Radiopharmaceuticals Product Portfolios and Specifications
13.6.3 SIEMENS SPECT and PET Diagnosis Radiopharmaceuticals Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 SIEMENS Main Business Overview
13.6.5 SIEMENS Latest Developments
13.7 Lantheus
13.7.1 Lantheus Company Information
13.7.2 Lantheus SPECT and PET Diagnosis Radiopharmaceuticals Product Portfolios and Specifications
13.7.3 Lantheus SPECT and PET Diagnosis Radiopharmaceuticals Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Lantheus Main Business Overview
13.7.5 Lantheus Latest Developments
13.8 Bracco Imaging
13.8.1 Bracco Imaging Company Information
13.8.2 Bracco Imaging SPECT and PET Diagnosis Radiopharmaceuticals Product Portfolios and Specifications
13.8.3 Bracco Imaging SPECT and PET Diagnosis Radiopharmaceuticals Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Bracco Imaging Main Business Overview
13.8.5 Bracco Imaging Latest Developments
13.9 Eli Lilly
13.9.1 Eli Lilly Company Information
13.9.2 Eli Lilly SPECT and PET Diagnosis Radiopharmaceuticals Product Portfolios and Specifications
13.9.3 Eli Lilly SPECT and PET Diagnosis Radiopharmaceuticals Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Eli Lilly Main Business Overview
13.9.5 Eli Lilly Latest Developments
13.10 China Isotope & Radiation
13.10.1 China Isotope & Radiation Company Information
13.10.2 China Isotope & Radiation SPECT and PET Diagnosis Radiopharmaceuticals Product Portfolios and Specifications
13.10.3 China Isotope & Radiation SPECT and PET Diagnosis Radiopharmaceuticals Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 China Isotope & Radiation Main Business Overview
13.10.5 China Isotope & Radiation Latest Developments
13.11 Dongcheng
13.11.1 Dongcheng Company Information
13.11.2 Dongcheng SPECT and PET Diagnosis Radiopharmaceuticals Product Portfolios and Specifications
13.11.3 Dongcheng SPECT and PET Diagnosis Radiopharmaceuticals Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Dongcheng Main Business Overview
13.11.5 Dongcheng Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global SPECT and PET Diagnosis Radiopharmaceuticals Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for SPECT and PET Diagnosis Radiopharmaceuticals by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for SPECT and PET Diagnosis Radiopharmaceuticals by Country/Region, 2021, 2025 & 2032
2.2 SPECT and PET Diagnosis Radiopharmaceuticals Segment by Type
2.2.1 Technetium
2.2.2 Fluorine
2.2.3 Other
2.2.4 SPECT and PET Diagnosis Radiopharmaceuticals Sales by Type
2.2.4.1 Global SPECT and PET Diagnosis Radiopharmaceuticals Sales Market Share by Type (2021-2026)
2.2.4.2 Global SPECT and PET Diagnosis Radiopharmaceuticals Revenue and Market Share by Type (2021-2026)
2.2.4.3 Global SPECT and PET Diagnosis Radiopharmaceuticals Sale Price by Type (2021-2026)
2.3 SPECT and PET Diagnosis Radiopharmaceuticals Segment by Imaging Modality
2.3.1 PET Imaging
2.3.2 SPECT Imaging
2.3.3 SPECT and PET Diagnosis Radiopharmaceuticals Sales by Imaging Modality
2.3.3.1 Global SPECT and PET Diagnosis Radiopharmaceuticals Sales Market Share by Imaging Modality (2021-2026)
2.3.3.2 Global SPECT and PET Diagnosis Radiopharmaceuticals Revenue and Market Share by Imaging Modality (2021-2026)
2.3.3.3 Global SPECT and PET Diagnosis Radiopharmaceuticals Sale Price by Imaging Modality (2021-2026)
2.4 SPECT and PET Diagnosis Radiopharmaceuticals Segment by End User
2.4.1 Hospitals
2.4.2 Imaging Centers
2.4.3 Other
2.4.4 SPECT and PET Diagnosis Radiopharmaceuticals Sales by End User
2.4.4.1 Global SPECT and PET Diagnosis Radiopharmaceuticals Sales Market Share by End User (2021-2026)
2.4.4.2 Global SPECT and PET Diagnosis Radiopharmaceuticals Revenue and Market Share by End User (2021-2026)
2.4.4.3 Global SPECT and PET Diagnosis Radiopharmaceuticals Sale Price by End User (2021-2026)
2.5 SPECT and PET Diagnosis Radiopharmaceuticals Segment by Application
2.5.1 Oncology
2.5.2 Cardiology
2.5.3 Other
2.5.4 SPECT and PET Diagnosis Radiopharmaceuticals Sales by Application
2.5.4.1 Global SPECT and PET Diagnosis Radiopharmaceuticals Sale Market Share by Application (2021-2026)
2.5.4.2 Global SPECT and PET Diagnosis Radiopharmaceuticals Revenue and Market Share by Application (2021-2026)
2.5.4.3 Global SPECT and PET Diagnosis Radiopharmaceuticals Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global SPECT and PET Diagnosis Radiopharmaceuticals Breakdown Data by Company
3.1.1 Global SPECT and PET Diagnosis Radiopharmaceuticals Annual Sales by Company (2021-2026)
3.1.2 Global SPECT and PET Diagnosis Radiopharmaceuticals Sales Market Share by Company (2021-2026)
3.2 Global SPECT and PET Diagnosis Radiopharmaceuticals Annual Revenue by Company (2021-2026)
3.2.1 Global SPECT and PET Diagnosis Radiopharmaceuticals Revenue by Company (2021-2026)
3.2.2 Global SPECT and PET Diagnosis Radiopharmaceuticals Revenue Market Share by Company (2021-2026)
3.3 Global SPECT and PET Diagnosis Radiopharmaceuticals Sale Price by Company
3.4 Key Manufacturers SPECT and PET Diagnosis Radiopharmaceuticals Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers SPECT and PET Diagnosis Radiopharmaceuticals Product Location Distribution
3.4.2 Players SPECT and PET Diagnosis Radiopharmaceuticals Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR SPECT AND PET DIAGNOSIS RADIOPHARMACEUTICALS BY GEOGRAPHIC REGION
4.1 World Historic SPECT and PET Diagnosis Radiopharmaceuticals Market Size by Geographic Region (2021-2026)
4.1.1 Global SPECT and PET Diagnosis Radiopharmaceuticals Annual Sales by Geographic Region (2021-2026)
4.1.2 Global SPECT and PET Diagnosis Radiopharmaceuticals Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic SPECT and PET Diagnosis Radiopharmaceuticals Market Size by Country/Region (2021-2026)
4.2.1 Global SPECT and PET Diagnosis Radiopharmaceuticals Annual Sales by Country/Region (2021-2026)
4.2.2 Global SPECT and PET Diagnosis Radiopharmaceuticals Annual Revenue by Country/Region (2021-2026)
4.3 Americas SPECT and PET Diagnosis Radiopharmaceuticals Sales Growth
4.4 APAC SPECT and PET Diagnosis Radiopharmaceuticals Sales Growth
4.5 Europe SPECT and PET Diagnosis Radiopharmaceuticals Sales Growth
4.6 Middle East & Africa SPECT and PET Diagnosis Radiopharmaceuticals Sales Growth
5 AMERICAS
5.1 Americas SPECT and PET Diagnosis Radiopharmaceuticals Sales by Country
5.1.1 Americas SPECT and PET Diagnosis Radiopharmaceuticals Sales by Country (2021-2026)
5.1.2 Americas SPECT and PET Diagnosis Radiopharmaceuticals Revenue by Country (2021-2026)
5.2 Americas SPECT and PET Diagnosis Radiopharmaceuticals Sales by Type (2021-2026)
5.3 Americas SPECT and PET Diagnosis Radiopharmaceuticals Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC SPECT and PET Diagnosis Radiopharmaceuticals Sales by Region
6.1.1 APAC SPECT and PET Diagnosis Radiopharmaceuticals Sales by Region (2021-2026)
6.1.2 APAC SPECT and PET Diagnosis Radiopharmaceuticals Revenue by Region (2021-2026)
6.2 APAC SPECT and PET Diagnosis Radiopharmaceuticals Sales by Type (2021-2026)
6.3 APAC SPECT and PET Diagnosis Radiopharmaceuticals Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe SPECT and PET Diagnosis Radiopharmaceuticals by Country
7.1.1 Europe SPECT and PET Diagnosis Radiopharmaceuticals Sales by Country (2021-2026)
7.1.2 Europe SPECT and PET Diagnosis Radiopharmaceuticals Revenue by Country (2021-2026)
7.2 Europe SPECT and PET Diagnosis Radiopharmaceuticals Sales by Type (2021-2026)
7.3 Europe SPECT and PET Diagnosis Radiopharmaceuticals Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa SPECT and PET Diagnosis Radiopharmaceuticals by Country
8.1.1 Middle East & Africa SPECT and PET Diagnosis Radiopharmaceuticals Sales by Country (2021-2026)
8.1.2 Middle East & Africa SPECT and PET Diagnosis Radiopharmaceuticals Revenue by Country (2021-2026)
8.2 Middle East & Africa SPECT and PET Diagnosis Radiopharmaceuticals Sales by Type (2021-2026)
8.3 Middle East & Africa SPECT and PET Diagnosis Radiopharmaceuticals Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of SPECT and PET Diagnosis Radiopharmaceuticals
10.3 Manufacturing Process Analysis of SPECT and PET Diagnosis Radiopharmaceuticals
10.4 Industry Chain Structure of SPECT and PET Diagnosis Radiopharmaceuticals
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 SPECT and PET Diagnosis Radiopharmaceuticals Distributors
11.3 SPECT and PET Diagnosis Radiopharmaceuticals Customer
12 WORLD FORECAST REVIEW FOR SPECT AND PET DIAGNOSIS RADIOPHARMACEUTICALS BY GEOGRAPHIC REGION
12.1 Global SPECT and PET Diagnosis Radiopharmaceuticals Market Size Forecast by Region
12.1.1 Global SPECT and PET Diagnosis Radiopharmaceuticals Forecast by Region (2027-2032)
12.1.2 Global SPECT and PET Diagnosis Radiopharmaceuticals Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global SPECT and PET Diagnosis Radiopharmaceuticals Forecast by Type (2027-2032)
12.7 Global SPECT and PET Diagnosis Radiopharmaceuticals Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Cardinal Health
13.1.1 Cardinal Health Company Information
13.1.2 Cardinal Health SPECT and PET Diagnosis Radiopharmaceuticals Product Portfolios and Specifications
13.1.3 Cardinal Health SPECT and PET Diagnosis Radiopharmaceuticals Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Cardinal Health Main Business Overview
13.1.5 Cardinal Health Latest Developments
13.2 GE Healthcare
13.2.1 GE Healthcare Company Information
13.2.2 GE Healthcare SPECT and PET Diagnosis Radiopharmaceuticals Product Portfolios and Specifications
13.2.3 GE Healthcare SPECT and PET Diagnosis Radiopharmaceuticals Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 GE Healthcare Main Business Overview
13.2.5 GE Healthcare Latest Developments
13.3 Jubilant Pharma
13.3.1 Jubilant Pharma Company Information
13.3.2 Jubilant Pharma SPECT and PET Diagnosis Radiopharmaceuticals Product Portfolios and Specifications
13.3.3 Jubilant Pharma SPECT and PET Diagnosis Radiopharmaceuticals Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Jubilant Pharma Main Business Overview
13.3.5 Jubilant Pharma Latest Developments
13.4 Novartis
13.4.1 Novartis Company Information
13.4.2 Novartis SPECT and PET Diagnosis Radiopharmaceuticals Product Portfolios and Specifications
13.4.3 Novartis SPECT and PET Diagnosis Radiopharmaceuticals Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Novartis Main Business Overview
13.4.5 Novartis Latest Developments
13.5 Curium Pharma
13.5.1 Curium Pharma Company Information
13.5.2 Curium Pharma SPECT and PET Diagnosis Radiopharmaceuticals Product Portfolios and Specifications
13.5.3 Curium Pharma SPECT and PET Diagnosis Radiopharmaceuticals Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Curium Pharma Main Business Overview
13.5.5 Curium Pharma Latest Developments
13.6 SIEMENS
13.6.1 SIEMENS Company Information
13.6.2 SIEMENS SPECT and PET Diagnosis Radiopharmaceuticals Product Portfolios and Specifications
13.6.3 SIEMENS SPECT and PET Diagnosis Radiopharmaceuticals Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 SIEMENS Main Business Overview
13.6.5 SIEMENS Latest Developments
13.7 Lantheus
13.7.1 Lantheus Company Information
13.7.2 Lantheus SPECT and PET Diagnosis Radiopharmaceuticals Product Portfolios and Specifications
13.7.3 Lantheus SPECT and PET Diagnosis Radiopharmaceuticals Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Lantheus Main Business Overview
13.7.5 Lantheus Latest Developments
13.8 Bracco Imaging
13.8.1 Bracco Imaging Company Information
13.8.2 Bracco Imaging SPECT and PET Diagnosis Radiopharmaceuticals Product Portfolios and Specifications
13.8.3 Bracco Imaging SPECT and PET Diagnosis Radiopharmaceuticals Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Bracco Imaging Main Business Overview
13.8.5 Bracco Imaging Latest Developments
13.9 Eli Lilly
13.9.1 Eli Lilly Company Information
13.9.2 Eli Lilly SPECT and PET Diagnosis Radiopharmaceuticals Product Portfolios and Specifications
13.9.3 Eli Lilly SPECT and PET Diagnosis Radiopharmaceuticals Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Eli Lilly Main Business Overview
13.9.5 Eli Lilly Latest Developments
13.10 China Isotope & Radiation
13.10.1 China Isotope & Radiation Company Information
13.10.2 China Isotope & Radiation SPECT and PET Diagnosis Radiopharmaceuticals Product Portfolios and Specifications
13.10.3 China Isotope & Radiation SPECT and PET Diagnosis Radiopharmaceuticals Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 China Isotope & Radiation Main Business Overview
13.10.5 China Isotope & Radiation Latest Developments
13.11 Dongcheng
13.11.1 Dongcheng Company Information
13.11.2 Dongcheng SPECT and PET Diagnosis Radiopharmaceuticals Product Portfolios and Specifications
13.11.3 Dongcheng SPECT and PET Diagnosis Radiopharmaceuticals Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Dongcheng Main Business Overview
13.11.5 Dongcheng Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. SPECT and PET Diagnosis Radiopharmaceuticals Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. SPECT and PET Diagnosis Radiopharmaceuticals Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Technetium 99
Table 4. Major Players of Fluorine 18
Table 5. Major Players of Other
Table 6. Global SPECT and PET Diagnosis Radiopharmaceuticals Sales by Type (2021-2026) & (K Dose)
Table 7. Global SPECT and PET Diagnosis Radiopharmaceuticals Sales Market Share by Type (2021-2026)
Table 8. Global SPECT and PET Diagnosis Radiopharmaceuticals Revenue by Type (2021-2026) & ($ million)
Table 9. Global SPECT and PET Diagnosis Radiopharmaceuticals Revenue Market Share by Type (2021-2026)
Table 10. Global SPECT and PET Diagnosis Radiopharmaceuticals Sale Price by Type (2021-2026) & (US$/Dose)
Table 11. Major Players of PET Imaging
Table 12. Major Players of SPECT Imaging
Table 13. Global SPECT and PET Diagnosis Radiopharmaceuticals Sales by Imaging Modality (2021-2026) & (K Dose)
Table 14. Global SPECT and PET Diagnosis Radiopharmaceuticals Sales Market Share by Imaging Modality (2021-2026)
Table 15. Global SPECT and PET Diagnosis Radiopharmaceuticals Revenue by Imaging Modality (2021-2026) & ($ million)
Table 16. Global SPECT and PET Diagnosis Radiopharmaceuticals Revenue Market Share by Imaging Modality (2021-2026)
Table 17. Global SPECT and PET Diagnosis Radiopharmaceuticals Sale Price by Imaging Modality (2021-2026) & (US$/Dose)
Table 18. Major Players of Hospitals
Table 19. Major Players of Imaging Centers
Table 20. Major Players of Other
Table 21. Global SPECT and PET Diagnosis Radiopharmaceuticals Sales by End User (2021-2026) & (K Dose)
Table 22. Global SPECT and PET Diagnosis Radiopharmaceuticals Sales Market Share by End User (2021-2026)
Table 23. Global SPECT and PET Diagnosis Radiopharmaceuticals Revenue by End User (2021-2026) & ($ million)
Table 24. Global SPECT and PET Diagnosis Radiopharmaceuticals Revenue Market Share by End User (2021-2026)
Table 25. Global SPECT and PET Diagnosis Radiopharmaceuticals Sale Price by End User (2021-2026) & (US$/Dose)
Table 26. Global SPECT and PET Diagnosis Radiopharmaceuticals Sale by Application (2021-2026) & (K Dose)
Table 27. Global SPECT and PET Diagnosis Radiopharmaceuticals Sale Market Share by Application (2021-2026)
Table 28. Global SPECT and PET Diagnosis Radiopharmaceuticals Revenue by Application (2021-2026) & ($ million)
Table 29. Global SPECT and PET Diagnosis Radiopharmaceuticals Revenue Market Share by Application (2021-2026)
Table 30. Global SPECT and PET Diagnosis Radiopharmaceuticals Sale Price by Application (2021-2026) & (US$/Dose)
Table 31. Global SPECT and PET Diagnosis Radiopharmaceuticals Sales by Company (2021-2026) & (K Dose)
Table 32. Global SPECT and PET Diagnosis Radiopharmaceuticals Sales Market Share by Company (2021-2026)
Table 33. Global SPECT and PET Diagnosis Radiopharmaceuticals Revenue by Company (2021-2026) & ($ millions)
Table 34. Global SPECT and PET Diagnosis Radiopharmaceuticals Revenue Market Share by Company (2021-2026)
Table 35. Global SPECT and PET Diagnosis Radiopharmaceuticals Sale Price by Company (2021-2026) & (US$/Dose)
Table 36. Key Manufacturers SPECT and PET Diagnosis Radiopharmaceuticals Producing Area Distribution and Sales Area
Table 37. Players SPECT and PET Diagnosis Radiopharmaceuticals Products Offered
Table 38. SPECT and PET Diagnosis Radiopharmaceuticals Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 39. New Products and Potential Entrants
Table 40. Market M&A Activity & Strategy
Table 41. Global SPECT and PET Diagnosis Radiopharmaceuticals Sales by Geographic Region (2021-2026) & (K Dose)
Table 42. Global SPECT and PET Diagnosis Radiopharmaceuticals Sales Market Share Geographic Region (2021-2026)
Table 43. Global SPECT and PET Diagnosis Radiopharmaceuticals Revenue by Geographic Region (2021-2026) & ($ millions)
Table 44. Global SPECT and PET Diagnosis Radiopharmaceuticals Revenue Market Share by Geographic Region (2021-2026)
Table 45. Global SPECT and PET Diagnosis Radiopharmaceuticals Sales by Country/Region (2021-2026) & (K Dose)
Table 46. Global SPECT and PET Diagnosis Radiopharmaceuticals Sales Market Share by Country/Region (2021-2026)
Table 47. Global SPECT and PET Diagnosis Radiopharmaceuticals Revenue by Country/Region (2021-2026) & ($ millions)
Table 48. Global SPECT and PET Diagnosis Radiopharmaceuticals Revenue Market Share by Country/Region (2021-2026)
Table 49. Americas SPECT and PET Diagnosis Radiopharmaceuticals Sales by Country (2021-2026) & (K Dose)
Table 50. Americas SPECT and PET Diagnosis Radiopharmaceuticals Sales Market Share by Country (2021-2026)
Table 51. Americas SPECT and PET Diagnosis Radiopharmaceuticals Revenue by Country (2021-2026) & ($ millions)
Table 52. Americas SPECT and PET Diagnosis Radiopharmaceuticals Sales by Type (2021-2026) & (K Dose)
Table 53. Americas SPECT and PET Diagnosis Radiopharmaceuticals Sales by Application (2021-2026) & (K Dose)
Table 54. APAC SPECT and PET Diagnosis Radiopharmaceuticals Sales by Region (2021-2026) & (K Dose)
Table 55. APAC SPECT and PET Diagnosis Radiopharmaceuticals Sales Market Share by Region (2021-2026)
Table 56. APAC SPECT and PET Diagnosis Radiopharmaceuticals Revenue by Region (2021-2026) & ($ millions)
Table 57. APAC SPECT and PET Diagnosis Radiopharmaceuticals Sales by Type (2021-2026) & (K Dose)
Table 58. APAC SPECT and PET Diagnosis Radiopharmaceuticals Sales by Application (2021-2026) & (K Dose)
Table 59. Europe SPECT and PET Diagnosis Radiopharmaceuticals Sales by Country (2021-2026) & (K Dose)
Table 60. Europe SPECT and PET Diagnosis Radiopharmaceuticals Revenue by Country (2021-2026) & ($ millions)
Table 61. Europe SPECT and PET Diagnosis Radiopharmaceuticals Sales by Type (2021-2026) & (K Dose)
Table 62. Europe SPECT and PET Diagnosis Radiopharmaceuticals Sales by Application (2021-2026) & (K Dose)
Table 63. Middle East & Africa SPECT and PET Diagnosis Radiopharmaceuticals Sales by Country (2021-2026) & (K Dose)
Table 64. Middle East & Africa SPECT and PET Diagnosis Radiopharmaceuticals Revenue Market Share by Country (2021-2026)
Table 65. Middle East & Africa SPECT and PET Diagnosis Radiopharmaceuticals Sales by Type (2021-2026) & (K Dose)
Table 66. Middle East & Africa SPECT and PET Diagnosis Radiopharmaceuticals Sales by Application (2021-2026) & (K Dose)
Table 67. Key Market Drivers & Growth Opportunities of SPECT and PET Diagnosis Radiopharmaceuticals
Table 68. Key Market Challenges & Risks of SPECT and PET Diagnosis Radiopharmaceuticals
Table 69. Key Industry Trends of SPECT and PET Diagnosis Radiopharmaceuticals
Table 70. SPECT and PET Diagnosis Radiopharmaceuticals Raw Material
Table 71. Key Suppliers of Raw Materials
Table 72. SPECT and PET Diagnosis Radiopharmaceuticals Distributors List
Table 73. SPECT and PET Diagnosis Radiopharmaceuticals Customer List
Table 74. Global SPECT and PET Diagnosis Radiopharmaceuticals Sales Forecast by Region (2027-2032) & (K Dose)
Table 75. Global SPECT and PET Diagnosis Radiopharmaceuticals Revenue Forecast by Region (2027-2032) & ($ millions)
Table 76. Americas SPECT and PET Diagnosis Radiopharmaceuticals Sales Forecast by Country (2027-2032) & (K Dose)
Table 77. Americas SPECT and PET Diagnosis Radiopharmaceuticals Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 78. APAC SPECT and PET Diagnosis Radiopharmaceuticals Sales Forecast by Region (2027-2032) & (K Dose)
Table 79. APAC SPECT and PET Diagnosis Radiopharmaceuticals Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 80. Europe SPECT and PET Diagnosis Radiopharmaceuticals Sales Forecast by Country (2027-2032) & (K Dose)
Table 81. Europe SPECT and PET Diagnosis Radiopharmaceuticals Revenue Forecast by Country (2027-2032) & ($ millions)
Table 82. Middle East & Africa SPECT and PET Diagnosis Radiopharmaceuticals Sales Forecast by Country (2027-2032) & (K Dose)
Table 83. Middle East & Africa SPECT and PET Diagnosis Radiopharmaceuticals Revenue Forecast by Country (2027-2032) & ($ millions)
Table 84. Global SPECT and PET Diagnosis Radiopharmaceuticals Sales Forecast by Type (2027-2032) & (K Dose)
Table 85. Global SPECT and PET Diagnosis Radiopharmaceuticals Revenue Forecast by Type (2027-2032) & ($ millions)
Table 86. Global SPECT and PET Diagnosis Radiopharmaceuticals Sales Forecast by Application (2027-2032) & (K Dose)
Table 87. Global SPECT and PET Diagnosis Radiopharmaceuticals Revenue Forecast by Application (2027-2032) & ($ millions)
Table 88. Cardinal Health Basic Information, SPECT and PET Diagnosis Radiopharmaceuticals Manufacturing Base, Sales Area and Its Competitors
Table 89. Cardinal Health SPECT and PET Diagnosis Radiopharmaceuticals Product Portfolios and Specifications
Table 90. Cardinal Health SPECT and PET Diagnosis Radiopharmaceuticals Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 91. Cardinal Health Main Business
Table 92. Cardinal Health Latest Developments
Table 93. GE Healthcare Basic Information, SPECT and PET Diagnosis Radiopharmaceuticals Manufacturing Base, Sales Area and Its Competitors
Table 94. GE Healthcare SPECT and PET Diagnosis Radiopharmaceuticals Product Portfolios and Specifications
Table 95. GE Healthcare SPECT and PET Diagnosis Radiopharmaceuticals Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 96. GE Healthcare Main Business
Table 97. GE Healthcare Latest Developments
Table 98. Jubilant Pharma Basic Information, SPECT and PET Diagnosis Radiopharmaceuticals Manufacturing Base, Sales Area and Its Competitors
Table 99. Jubilant Pharma SPECT and PET Diagnosis Radiopharmaceuticals Product Portfolios and Specifications
Table 100. Jubilant Pharma SPECT and PET Diagnosis Radiopharmaceuticals Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 101. Jubilant Pharma Main Business
Table 102. Jubilant Pharma Latest Developments
Table 103. Novartis Basic Information, SPECT and PET Diagnosis Radiopharmaceuticals Manufacturing Base, Sales Area and Its Competitors
Table 104. Novartis SPECT and PET Diagnosis Radiopharmaceuticals Product Portfolios and Specifications
Table 105. Novartis SPECT and PET Diagnosis Radiopharmaceuticals Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 106. Novartis Main Business
Table 107. Novartis Latest Developments
Table 108. Curium Pharma Basic Information, SPECT and PET Diagnosis Radiopharmaceuticals Manufacturing Base, Sales Area and Its Competitors
Table 109. Curium Pharma SPECT and PET Diagnosis Radiopharmaceuticals Product Portfolios and Specifications
Table 110. Curium Pharma SPECT and PET Diagnosis Radiopharmaceuticals Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 111. Curium Pharma Main Business
Table 112. Curium Pharma Latest Developments
Table 113. SIEMENS Basic Information, SPECT and PET Diagnosis Radiopharmaceuticals Manufacturing Base, Sales Area and Its Competitors
Table 114. SIEMENS SPECT and PET Diagnosis Radiopharmaceuticals Product Portfolios and Specifications
Table 115. SIEMENS SPECT and PET Diagnosis Radiopharmaceuticals Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 116. SIEMENS Main Business
Table 117. SIEMENS Latest Developments
Table 118. Lantheus Basic Information, SPECT and PET Diagnosis Radiopharmaceuticals Manufacturing Base, Sales Area and Its Competitors
Table 119. Lantheus SPECT and PET Diagnosis Radiopharmaceuticals Product Portfolios and Specifications
Table 120. Lantheus SPECT and PET Diagnosis Radiopharmaceuticals Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 121. Lantheus Main Business
Table 122. Lantheus Latest Developments
Table 123. Bracco Imaging Basic Information, SPECT and PET Diagnosis Radiopharmaceuticals Manufacturing Base, Sales Area and Its Competitors
Table 124. Bracco Imaging SPECT and PET Diagnosis Radiopharmaceuticals Product Portfolios and Specifications
Table 125. Bracco Imaging SPECT and PET Diagnosis Radiopharmaceuticals Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 126. Bracco Imaging Main Business
Table 127. Bracco Imaging Latest Developments
Table 128. Eli Lilly Basic Information, SPECT and PET Diagnosis Radiopharmaceuticals Manufacturing Base, Sales Area and Its Competitors
Table 129. Eli Lilly SPECT and PET Diagnosis Radiopharmaceuticals Product Portfolios and Specifications
Table 130. Eli Lilly SPECT and PET Diagnosis Radiopharmaceuticals Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 131. Eli Lilly Main Business
Table 132. Eli Lilly Latest Developments
Table 133. China Isotope & Radiation Basic Information, SPECT and PET Diagnosis Radiopharmaceuticals Manufacturing Base, Sales Area and Its Competitors
Table 134. China Isotope & Radiation SPECT and PET Diagnosis Radiopharmaceuticals Product Portfolios and Specifications
Table 135. China Isotope & Radiation SPECT and PET Diagnosis Radiopharmaceuticals Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 136. China Isotope & Radiation Main Business
Table 137. China Isotope & Radiation Latest Developments
Table 138. Dongcheng Basic Information, SPECT and PET Diagnosis Radiopharmaceuticals Manufacturing Base, Sales Area and Its Competitors
Table 139. Dongcheng SPECT and PET Diagnosis Radiopharmaceuticals Product Portfolios and Specifications
Table 140. Dongcheng SPECT and PET Diagnosis Radiopharmaceuticals Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 141. Dongcheng Main Business
Table 142. Dongcheng Latest Developments
Table 1. SPECT and PET Diagnosis Radiopharmaceuticals Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. SPECT and PET Diagnosis Radiopharmaceuticals Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Technetium 99
Table 4. Major Players of Fluorine 18
Table 5. Major Players of Other
Table 6. Global SPECT and PET Diagnosis Radiopharmaceuticals Sales by Type (2021-2026) & (K Dose)
Table 7. Global SPECT and PET Diagnosis Radiopharmaceuticals Sales Market Share by Type (2021-2026)
Table 8. Global SPECT and PET Diagnosis Radiopharmaceuticals Revenue by Type (2021-2026) & ($ million)
Table 9. Global SPECT and PET Diagnosis Radiopharmaceuticals Revenue Market Share by Type (2021-2026)
Table 10. Global SPECT and PET Diagnosis Radiopharmaceuticals Sale Price by Type (2021-2026) & (US$/Dose)
Table 11. Major Players of PET Imaging
Table 12. Major Players of SPECT Imaging
Table 13. Global SPECT and PET Diagnosis Radiopharmaceuticals Sales by Imaging Modality (2021-2026) & (K Dose)
Table 14. Global SPECT and PET Diagnosis Radiopharmaceuticals Sales Market Share by Imaging Modality (2021-2026)
Table 15. Global SPECT and PET Diagnosis Radiopharmaceuticals Revenue by Imaging Modality (2021-2026) & ($ million)
Table 16. Global SPECT and PET Diagnosis Radiopharmaceuticals Revenue Market Share by Imaging Modality (2021-2026)
Table 17. Global SPECT and PET Diagnosis Radiopharmaceuticals Sale Price by Imaging Modality (2021-2026) & (US$/Dose)
Table 18. Major Players of Hospitals
Table 19. Major Players of Imaging Centers
Table 20. Major Players of Other
Table 21. Global SPECT and PET Diagnosis Radiopharmaceuticals Sales by End User (2021-2026) & (K Dose)
Table 22. Global SPECT and PET Diagnosis Radiopharmaceuticals Sales Market Share by End User (2021-2026)
Table 23. Global SPECT and PET Diagnosis Radiopharmaceuticals Revenue by End User (2021-2026) & ($ million)
Table 24. Global SPECT and PET Diagnosis Radiopharmaceuticals Revenue Market Share by End User (2021-2026)
Table 25. Global SPECT and PET Diagnosis Radiopharmaceuticals Sale Price by End User (2021-2026) & (US$/Dose)
Table 26. Global SPECT and PET Diagnosis Radiopharmaceuticals Sale by Application (2021-2026) & (K Dose)
Table 27. Global SPECT and PET Diagnosis Radiopharmaceuticals Sale Market Share by Application (2021-2026)
Table 28. Global SPECT and PET Diagnosis Radiopharmaceuticals Revenue by Application (2021-2026) & ($ million)
Table 29. Global SPECT and PET Diagnosis Radiopharmaceuticals Revenue Market Share by Application (2021-2026)
Table 30. Global SPECT and PET Diagnosis Radiopharmaceuticals Sale Price by Application (2021-2026) & (US$/Dose)
Table 31. Global SPECT and PET Diagnosis Radiopharmaceuticals Sales by Company (2021-2026) & (K Dose)
Table 32. Global SPECT and PET Diagnosis Radiopharmaceuticals Sales Market Share by Company (2021-2026)
Table 33. Global SPECT and PET Diagnosis Radiopharmaceuticals Revenue by Company (2021-2026) & ($ millions)
Table 34. Global SPECT and PET Diagnosis Radiopharmaceuticals Revenue Market Share by Company (2021-2026)
Table 35. Global SPECT and PET Diagnosis Radiopharmaceuticals Sale Price by Company (2021-2026) & (US$/Dose)
Table 36. Key Manufacturers SPECT and PET Diagnosis Radiopharmaceuticals Producing Area Distribution and Sales Area
Table 37. Players SPECT and PET Diagnosis Radiopharmaceuticals Products Offered
Table 38. SPECT and PET Diagnosis Radiopharmaceuticals Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 39. New Products and Potential Entrants
Table 40. Market M&A Activity & Strategy
Table 41. Global SPECT and PET Diagnosis Radiopharmaceuticals Sales by Geographic Region (2021-2026) & (K Dose)
Table 42. Global SPECT and PET Diagnosis Radiopharmaceuticals Sales Market Share Geographic Region (2021-2026)
Table 43. Global SPECT and PET Diagnosis Radiopharmaceuticals Revenue by Geographic Region (2021-2026) & ($ millions)
Table 44. Global SPECT and PET Diagnosis Radiopharmaceuticals Revenue Market Share by Geographic Region (2021-2026)
Table 45. Global SPECT and PET Diagnosis Radiopharmaceuticals Sales by Country/Region (2021-2026) & (K Dose)
Table 46. Global SPECT and PET Diagnosis Radiopharmaceuticals Sales Market Share by Country/Region (2021-2026)
Table 47. Global SPECT and PET Diagnosis Radiopharmaceuticals Revenue by Country/Region (2021-2026) & ($ millions)
Table 48. Global SPECT and PET Diagnosis Radiopharmaceuticals Revenue Market Share by Country/Region (2021-2026)
Table 49. Americas SPECT and PET Diagnosis Radiopharmaceuticals Sales by Country (2021-2026) & (K Dose)
Table 50. Americas SPECT and PET Diagnosis Radiopharmaceuticals Sales Market Share by Country (2021-2026)
Table 51. Americas SPECT and PET Diagnosis Radiopharmaceuticals Revenue by Country (2021-2026) & ($ millions)
Table 52. Americas SPECT and PET Diagnosis Radiopharmaceuticals Sales by Type (2021-2026) & (K Dose)
Table 53. Americas SPECT and PET Diagnosis Radiopharmaceuticals Sales by Application (2021-2026) & (K Dose)
Table 54. APAC SPECT and PET Diagnosis Radiopharmaceuticals Sales by Region (2021-2026) & (K Dose)
Table 55. APAC SPECT and PET Diagnosis Radiopharmaceuticals Sales Market Share by Region (2021-2026)
Table 56. APAC SPECT and PET Diagnosis Radiopharmaceuticals Revenue by Region (2021-2026) & ($ millions)
Table 57. APAC SPECT and PET Diagnosis Radiopharmaceuticals Sales by Type (2021-2026) & (K Dose)
Table 58. APAC SPECT and PET Diagnosis Radiopharmaceuticals Sales by Application (2021-2026) & (K Dose)
Table 59. Europe SPECT and PET Diagnosis Radiopharmaceuticals Sales by Country (2021-2026) & (K Dose)
Table 60. Europe SPECT and PET Diagnosis Radiopharmaceuticals Revenue by Country (2021-2026) & ($ millions)
Table 61. Europe SPECT and PET Diagnosis Radiopharmaceuticals Sales by Type (2021-2026) & (K Dose)
Table 62. Europe SPECT and PET Diagnosis Radiopharmaceuticals Sales by Application (2021-2026) & (K Dose)
Table 63. Middle East & Africa SPECT and PET Diagnosis Radiopharmaceuticals Sales by Country (2021-2026) & (K Dose)
Table 64. Middle East & Africa SPECT and PET Diagnosis Radiopharmaceuticals Revenue Market Share by Country (2021-2026)
Table 65. Middle East & Africa SPECT and PET Diagnosis Radiopharmaceuticals Sales by Type (2021-2026) & (K Dose)
Table 66. Middle East & Africa SPECT and PET Diagnosis Radiopharmaceuticals Sales by Application (2021-2026) & (K Dose)
Table 67. Key Market Drivers & Growth Opportunities of SPECT and PET Diagnosis Radiopharmaceuticals
Table 68. Key Market Challenges & Risks of SPECT and PET Diagnosis Radiopharmaceuticals
Table 69. Key Industry Trends of SPECT and PET Diagnosis Radiopharmaceuticals
Table 70. SPECT and PET Diagnosis Radiopharmaceuticals Raw Material
Table 71. Key Suppliers of Raw Materials
Table 72. SPECT and PET Diagnosis Radiopharmaceuticals Distributors List
Table 73. SPECT and PET Diagnosis Radiopharmaceuticals Customer List
Table 74. Global SPECT and PET Diagnosis Radiopharmaceuticals Sales Forecast by Region (2027-2032) & (K Dose)
Table 75. Global SPECT and PET Diagnosis Radiopharmaceuticals Revenue Forecast by Region (2027-2032) & ($ millions)
Table 76. Americas SPECT and PET Diagnosis Radiopharmaceuticals Sales Forecast by Country (2027-2032) & (K Dose)
Table 77. Americas SPECT and PET Diagnosis Radiopharmaceuticals Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 78. APAC SPECT and PET Diagnosis Radiopharmaceuticals Sales Forecast by Region (2027-2032) & (K Dose)
Table 79. APAC SPECT and PET Diagnosis Radiopharmaceuticals Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 80. Europe SPECT and PET Diagnosis Radiopharmaceuticals Sales Forecast by Country (2027-2032) & (K Dose)
Table 81. Europe SPECT and PET Diagnosis Radiopharmaceuticals Revenue Forecast by Country (2027-2032) & ($ millions)
Table 82. Middle East & Africa SPECT and PET Diagnosis Radiopharmaceuticals Sales Forecast by Country (2027-2032) & (K Dose)
Table 83. Middle East & Africa SPECT and PET Diagnosis Radiopharmaceuticals Revenue Forecast by Country (2027-2032) & ($ millions)
Table 84. Global SPECT and PET Diagnosis Radiopharmaceuticals Sales Forecast by Type (2027-2032) & (K Dose)
Table 85. Global SPECT and PET Diagnosis Radiopharmaceuticals Revenue Forecast by Type (2027-2032) & ($ millions)
Table 86. Global SPECT and PET Diagnosis Radiopharmaceuticals Sales Forecast by Application (2027-2032) & (K Dose)
Table 87. Global SPECT and PET Diagnosis Radiopharmaceuticals Revenue Forecast by Application (2027-2032) & ($ millions)
Table 88. Cardinal Health Basic Information, SPECT and PET Diagnosis Radiopharmaceuticals Manufacturing Base, Sales Area and Its Competitors
Table 89. Cardinal Health SPECT and PET Diagnosis Radiopharmaceuticals Product Portfolios and Specifications
Table 90. Cardinal Health SPECT and PET Diagnosis Radiopharmaceuticals Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 91. Cardinal Health Main Business
Table 92. Cardinal Health Latest Developments
Table 93. GE Healthcare Basic Information, SPECT and PET Diagnosis Radiopharmaceuticals Manufacturing Base, Sales Area and Its Competitors
Table 94. GE Healthcare SPECT and PET Diagnosis Radiopharmaceuticals Product Portfolios and Specifications
Table 95. GE Healthcare SPECT and PET Diagnosis Radiopharmaceuticals Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 96. GE Healthcare Main Business
Table 97. GE Healthcare Latest Developments
Table 98. Jubilant Pharma Basic Information, SPECT and PET Diagnosis Radiopharmaceuticals Manufacturing Base, Sales Area and Its Competitors
Table 99. Jubilant Pharma SPECT and PET Diagnosis Radiopharmaceuticals Product Portfolios and Specifications
Table 100. Jubilant Pharma SPECT and PET Diagnosis Radiopharmaceuticals Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 101. Jubilant Pharma Main Business
Table 102. Jubilant Pharma Latest Developments
Table 103. Novartis Basic Information, SPECT and PET Diagnosis Radiopharmaceuticals Manufacturing Base, Sales Area and Its Competitors
Table 104. Novartis SPECT and PET Diagnosis Radiopharmaceuticals Product Portfolios and Specifications
Table 105. Novartis SPECT and PET Diagnosis Radiopharmaceuticals Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 106. Novartis Main Business
Table 107. Novartis Latest Developments
Table 108. Curium Pharma Basic Information, SPECT and PET Diagnosis Radiopharmaceuticals Manufacturing Base, Sales Area and Its Competitors
Table 109. Curium Pharma SPECT and PET Diagnosis Radiopharmaceuticals Product Portfolios and Specifications
Table 110. Curium Pharma SPECT and PET Diagnosis Radiopharmaceuticals Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 111. Curium Pharma Main Business
Table 112. Curium Pharma Latest Developments
Table 113. SIEMENS Basic Information, SPECT and PET Diagnosis Radiopharmaceuticals Manufacturing Base, Sales Area and Its Competitors
Table 114. SIEMENS SPECT and PET Diagnosis Radiopharmaceuticals Product Portfolios and Specifications
Table 115. SIEMENS SPECT and PET Diagnosis Radiopharmaceuticals Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 116. SIEMENS Main Business
Table 117. SIEMENS Latest Developments
Table 118. Lantheus Basic Information, SPECT and PET Diagnosis Radiopharmaceuticals Manufacturing Base, Sales Area and Its Competitors
Table 119. Lantheus SPECT and PET Diagnosis Radiopharmaceuticals Product Portfolios and Specifications
Table 120. Lantheus SPECT and PET Diagnosis Radiopharmaceuticals Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 121. Lantheus Main Business
Table 122. Lantheus Latest Developments
Table 123. Bracco Imaging Basic Information, SPECT and PET Diagnosis Radiopharmaceuticals Manufacturing Base, Sales Area and Its Competitors
Table 124. Bracco Imaging SPECT and PET Diagnosis Radiopharmaceuticals Product Portfolios and Specifications
Table 125. Bracco Imaging SPECT and PET Diagnosis Radiopharmaceuticals Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 126. Bracco Imaging Main Business
Table 127. Bracco Imaging Latest Developments
Table 128. Eli Lilly Basic Information, SPECT and PET Diagnosis Radiopharmaceuticals Manufacturing Base, Sales Area and Its Competitors
Table 129. Eli Lilly SPECT and PET Diagnosis Radiopharmaceuticals Product Portfolios and Specifications
Table 130. Eli Lilly SPECT and PET Diagnosis Radiopharmaceuticals Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 131. Eli Lilly Main Business
Table 132. Eli Lilly Latest Developments
Table 133. China Isotope & Radiation Basic Information, SPECT and PET Diagnosis Radiopharmaceuticals Manufacturing Base, Sales Area and Its Competitors
Table 134. China Isotope & Radiation SPECT and PET Diagnosis Radiopharmaceuticals Product Portfolios and Specifications
Table 135. China Isotope & Radiation SPECT and PET Diagnosis Radiopharmaceuticals Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 136. China Isotope & Radiation Main Business
Table 137. China Isotope & Radiation Latest Developments
Table 138. Dongcheng Basic Information, SPECT and PET Diagnosis Radiopharmaceuticals Manufacturing Base, Sales Area and Its Competitors
Table 139. Dongcheng SPECT and PET Diagnosis Radiopharmaceuticals Product Portfolios and Specifications
Table 140. Dongcheng SPECT and PET Diagnosis Radiopharmaceuticals Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 141. Dongcheng Main Business
Table 142. Dongcheng Latest Developments
LIST OF FIGURES
Figure 1. Picture of SPECT and PET Diagnosis Radiopharmaceuticals
Figure 2. SPECT and PET Diagnosis Radiopharmaceuticals Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global SPECT and PET Diagnosis Radiopharmaceuticals Sales Growth Rate 2021-2032 (K Dose)
Figure 7. Global SPECT and PET Diagnosis Radiopharmaceuticals Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. SPECT and PET Diagnosis Radiopharmaceuticals Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. SPECT and PET Diagnosis Radiopharmaceuticals Sales Market Share by Country/Region (2025)
Figure 10. SPECT and PET Diagnosis Radiopharmaceuticals Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Technetium 99
Figure 12. Product Picture of Fluorine 18
Figure 13. Product Picture of Other
Figure 14. Global SPECT and PET Diagnosis Radiopharmaceuticals Sales Market Share by Type in 2026
Figure 15. Global SPECT and PET Diagnosis Radiopharmaceuticals Revenue Market Share by Type (2021-2026)
Figure 16. Product Picture of PET Imaging
Figure 17. Product Picture of SPECT Imaging
Figure 18. Global SPECT and PET Diagnosis Radiopharmaceuticals Sales Market Share by Imaging Modality in 2026
Figure 19. Global SPECT and PET Diagnosis Radiopharmaceuticals Revenue Market Share by Imaging Modality (2021-2026)
Figure 20. Product Picture of Hospitals
Figure 21. Product Picture of Imaging Centers
Figure 22. Product Picture of Other
Figure 23. Global SPECT and PET Diagnosis Radiopharmaceuticals Sales Market Share by End User in 2026
Figure 24. Global SPECT and PET Diagnosis Radiopharmaceuticals Revenue Market Share by End User (2021-2026)
Figure 25. SPECT and PET Diagnosis Radiopharmaceuticals Consumed in Oncology
Figure 26. Global SPECT and PET Diagnosis Radiopharmaceuticals Market: Oncology (2021-2026) & (K Dose)
Figure 27. SPECT and PET Diagnosis Radiopharmaceuticals Consumed in Cardiology
Figure 28. Global SPECT and PET Diagnosis Radiopharmaceuticals Market: Cardiology (2021-2026) & (K Dose)
Figure 29. SPECT and PET Diagnosis Radiopharmaceuticals Consumed in Other
Figure 30. Global SPECT and PET Diagnosis Radiopharmaceuticals Market: Other (2021-2026) & (K Dose)
Figure 31. Global SPECT and PET Diagnosis Radiopharmaceuticals Sale Market Share by Application (2025)
Figure 32. Global SPECT and PET Diagnosis Radiopharmaceuticals Revenue Market Share by Application in 2025
Figure 33. SPECT and PET Diagnosis Radiopharmaceuticals Sales by Company in 2025 (K Dose)
Figure 34. Global SPECT and PET Diagnosis Radiopharmaceuticals Sales Market Share by Company in 2025
Figure 35. SPECT and PET Diagnosis Radiopharmaceuticals Revenue by Company in 2025 ($ millions)
Figure 36. Global SPECT and PET Diagnosis Radiopharmaceuticals Revenue Market Share by Company in 2025
Figure 37. Global SPECT and PET Diagnosis Radiopharmaceuticals Sales Market Share by Geographic Region (2021-2026)
Figure 38. Global SPECT and PET Diagnosis Radiopharmaceuticals Revenue Market Share by Geographic Region in 2025
Figure 39. Americas SPECT and PET Diagnosis Radiopharmaceuticals Sales 2021-2026 (K Dose)
Figure 40. Americas SPECT and PET Diagnosis Radiopharmaceuticals Revenue 2021-2026 ($ millions)
Figure 41. APAC SPECT and PET Diagnosis Radiopharmaceuticals Sales 2021-2026 (K Dose)
Figure 42. APAC SPECT and PET Diagnosis Radiopharmaceuticals Revenue 2021-2026 ($ millions)
Figure 43. Europe SPECT and PET Diagnosis Radiopharmaceuticals Sales 2021-2026 (K Dose)
Figure 44. Europe SPECT and PET Diagnosis Radiopharmaceuticals Revenue 2021-2026 ($ millions)
Figure 45. Middle East & Africa SPECT and PET Diagnosis Radiopharmaceuticals Sales 2021-2026 (K Dose)
Figure 46. Middle East & Africa SPECT and PET Diagnosis Radiopharmaceuticals Revenue 2021-2026 ($ millions)
Figure 47. Americas SPECT and PET Diagnosis Radiopharmaceuticals Sales Market Share by Country in 2025
Figure 48. Americas SPECT and PET Diagnosis Radiopharmaceuticals Revenue Market Share by Country (2021-2026)
Figure 49. Americas SPECT and PET Diagnosis Radiopharmaceuticals Sales Market Share by Type (2021-2026)
Figure 50. Americas SPECT and PET Diagnosis Radiopharmaceuticals Sales Market Share by Application (2021-2026)
Figure 51. United States SPECT and PET Diagnosis Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 52. Canada SPECT and PET Diagnosis Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 53. Mexico SPECT and PET Diagnosis Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 54. Brazil SPECT and PET Diagnosis Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 55. APAC SPECT and PET Diagnosis Radiopharmaceuticals Sales Market Share by Region in 2025
Figure 56. APAC SPECT and PET Diagnosis Radiopharmaceuticals Revenue Market Share by Region (2021-2026)
Figure 57. APAC SPECT and PET Diagnosis Radiopharmaceuticals Sales Market Share by Type (2021-2026)
Figure 58. APAC SPECT and PET Diagnosis Radiopharmaceuticals Sales Market Share by Application (2021-2026)
Figure 59. China SPECT and PET Diagnosis Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 60. Japan SPECT and PET Diagnosis Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 61. South Korea SPECT and PET Diagnosis Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 62. Southeast Asia SPECT and PET Diagnosis Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 63. India SPECT and PET Diagnosis Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 64. Australia SPECT and PET Diagnosis Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 65. China Taiwan SPECT and PET Diagnosis Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 66. Europe SPECT and PET Diagnosis Radiopharmaceuticals Sales Market Share by Country in 2025
Figure 67. Europe SPECT and PET Diagnosis Radiopharmaceuticals Revenue Market Share by Country (2021-2026)
Figure 68. Europe SPECT and PET Diagnosis Radiopharmaceuticals Sales Market Share by Type (2021-2026)
Figure 69. Europe SPECT and PET Diagnosis Radiopharmaceuticals Sales Market Share by Application (2021-2026)
Figure 70. Germany SPECT and PET Diagnosis Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 71. France SPECT and PET Diagnosis Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 72. UK SPECT and PET Diagnosis Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 73. Italy SPECT and PET Diagnosis Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 74. Russia SPECT and PET Diagnosis Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 75. Middle East & Africa SPECT and PET Diagnosis Radiopharmaceuticals Sales Market Share by Country (2021-2026)
Figure 76. Middle East & Africa SPECT and PET Diagnosis Radiopharmaceuticals Sales Market Share by Type (2021-2026)
Figure 77. Middle East & Africa SPECT and PET Diagnosis Radiopharmaceuticals Sales Market Share by Application (2021-2026)
Figure 78. Egypt SPECT and PET Diagnosis Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 79. South Africa SPECT and PET Diagnosis Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 80. Israel SPECT and PET Diagnosis Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 81. Turkey SPECT and PET Diagnosis Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 82. GCC Countries SPECT and PET Diagnosis Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 83. Manufacturing Cost Structure Analysis of SPECT and PET Diagnosis Radiopharmaceuticals in 2026
Figure 84. Manufacturing Process Analysis of SPECT and PET Diagnosis Radiopharmaceuticals
Figure 85. Industry Chain Structure of SPECT and PET Diagnosis Radiopharmaceuticals
Figure 86. Channels of Distribution
Figure 87. Global SPECT and PET Diagnosis Radiopharmaceuticals Sales Market Forecast by Region (2027-2032)
Figure 88. Global SPECT and PET Diagnosis Radiopharmaceuticals Revenue Market Share Forecast by Region (2027-2032)
Figure 89. Global SPECT and PET Diagnosis Radiopharmaceuticals Sales Market Share Forecast by Type (2027-2032)
Figure 90. Global SPECT and PET Diagnosis Radiopharmaceuticals Revenue Market Share Forecast by Type (2027-2032)
Figure 91. Global SPECT and PET Diagnosis Radiopharmaceuticals Sales Market Share Forecast by Application (2027-2032)
Figure 92. Global SPECT and PET Diagnosis Radiopharmaceuticals Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of SPECT and PET Diagnosis Radiopharmaceuticals
Figure 2. SPECT and PET Diagnosis Radiopharmaceuticals Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global SPECT and PET Diagnosis Radiopharmaceuticals Sales Growth Rate 2021-2032 (K Dose)
Figure 7. Global SPECT and PET Diagnosis Radiopharmaceuticals Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. SPECT and PET Diagnosis Radiopharmaceuticals Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. SPECT and PET Diagnosis Radiopharmaceuticals Sales Market Share by Country/Region (2025)
Figure 10. SPECT and PET Diagnosis Radiopharmaceuticals Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Technetium 99
Figure 12. Product Picture of Fluorine 18
Figure 13. Product Picture of Other
Figure 14. Global SPECT and PET Diagnosis Radiopharmaceuticals Sales Market Share by Type in 2026
Figure 15. Global SPECT and PET Diagnosis Radiopharmaceuticals Revenue Market Share by Type (2021-2026)
Figure 16. Product Picture of PET Imaging
Figure 17. Product Picture of SPECT Imaging
Figure 18. Global SPECT and PET Diagnosis Radiopharmaceuticals Sales Market Share by Imaging Modality in 2026
Figure 19. Global SPECT and PET Diagnosis Radiopharmaceuticals Revenue Market Share by Imaging Modality (2021-2026)
Figure 20. Product Picture of Hospitals
Figure 21. Product Picture of Imaging Centers
Figure 22. Product Picture of Other
Figure 23. Global SPECT and PET Diagnosis Radiopharmaceuticals Sales Market Share by End User in 2026
Figure 24. Global SPECT and PET Diagnosis Radiopharmaceuticals Revenue Market Share by End User (2021-2026)
Figure 25. SPECT and PET Diagnosis Radiopharmaceuticals Consumed in Oncology
Figure 26. Global SPECT and PET Diagnosis Radiopharmaceuticals Market: Oncology (2021-2026) & (K Dose)
Figure 27. SPECT and PET Diagnosis Radiopharmaceuticals Consumed in Cardiology
Figure 28. Global SPECT and PET Diagnosis Radiopharmaceuticals Market: Cardiology (2021-2026) & (K Dose)
Figure 29. SPECT and PET Diagnosis Radiopharmaceuticals Consumed in Other
Figure 30. Global SPECT and PET Diagnosis Radiopharmaceuticals Market: Other (2021-2026) & (K Dose)
Figure 31. Global SPECT and PET Diagnosis Radiopharmaceuticals Sale Market Share by Application (2025)
Figure 32. Global SPECT and PET Diagnosis Radiopharmaceuticals Revenue Market Share by Application in 2025
Figure 33. SPECT and PET Diagnosis Radiopharmaceuticals Sales by Company in 2025 (K Dose)
Figure 34. Global SPECT and PET Diagnosis Radiopharmaceuticals Sales Market Share by Company in 2025
Figure 35. SPECT and PET Diagnosis Radiopharmaceuticals Revenue by Company in 2025 ($ millions)
Figure 36. Global SPECT and PET Diagnosis Radiopharmaceuticals Revenue Market Share by Company in 2025
Figure 37. Global SPECT and PET Diagnosis Radiopharmaceuticals Sales Market Share by Geographic Region (2021-2026)
Figure 38. Global SPECT and PET Diagnosis Radiopharmaceuticals Revenue Market Share by Geographic Region in 2025
Figure 39. Americas SPECT and PET Diagnosis Radiopharmaceuticals Sales 2021-2026 (K Dose)
Figure 40. Americas SPECT and PET Diagnosis Radiopharmaceuticals Revenue 2021-2026 ($ millions)
Figure 41. APAC SPECT and PET Diagnosis Radiopharmaceuticals Sales 2021-2026 (K Dose)
Figure 42. APAC SPECT and PET Diagnosis Radiopharmaceuticals Revenue 2021-2026 ($ millions)
Figure 43. Europe SPECT and PET Diagnosis Radiopharmaceuticals Sales 2021-2026 (K Dose)
Figure 44. Europe SPECT and PET Diagnosis Radiopharmaceuticals Revenue 2021-2026 ($ millions)
Figure 45. Middle East & Africa SPECT and PET Diagnosis Radiopharmaceuticals Sales 2021-2026 (K Dose)
Figure 46. Middle East & Africa SPECT and PET Diagnosis Radiopharmaceuticals Revenue 2021-2026 ($ millions)
Figure 47. Americas SPECT and PET Diagnosis Radiopharmaceuticals Sales Market Share by Country in 2025
Figure 48. Americas SPECT and PET Diagnosis Radiopharmaceuticals Revenue Market Share by Country (2021-2026)
Figure 49. Americas SPECT and PET Diagnosis Radiopharmaceuticals Sales Market Share by Type (2021-2026)
Figure 50. Americas SPECT and PET Diagnosis Radiopharmaceuticals Sales Market Share by Application (2021-2026)
Figure 51. United States SPECT and PET Diagnosis Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 52. Canada SPECT and PET Diagnosis Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 53. Mexico SPECT and PET Diagnosis Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 54. Brazil SPECT and PET Diagnosis Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 55. APAC SPECT and PET Diagnosis Radiopharmaceuticals Sales Market Share by Region in 2025
Figure 56. APAC SPECT and PET Diagnosis Radiopharmaceuticals Revenue Market Share by Region (2021-2026)
Figure 57. APAC SPECT and PET Diagnosis Radiopharmaceuticals Sales Market Share by Type (2021-2026)
Figure 58. APAC SPECT and PET Diagnosis Radiopharmaceuticals Sales Market Share by Application (2021-2026)
Figure 59. China SPECT and PET Diagnosis Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 60. Japan SPECT and PET Diagnosis Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 61. South Korea SPECT and PET Diagnosis Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 62. Southeast Asia SPECT and PET Diagnosis Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 63. India SPECT and PET Diagnosis Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 64. Australia SPECT and PET Diagnosis Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 65. China Taiwan SPECT and PET Diagnosis Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 66. Europe SPECT and PET Diagnosis Radiopharmaceuticals Sales Market Share by Country in 2025
Figure 67. Europe SPECT and PET Diagnosis Radiopharmaceuticals Revenue Market Share by Country (2021-2026)
Figure 68. Europe SPECT and PET Diagnosis Radiopharmaceuticals Sales Market Share by Type (2021-2026)
Figure 69. Europe SPECT and PET Diagnosis Radiopharmaceuticals Sales Market Share by Application (2021-2026)
Figure 70. Germany SPECT and PET Diagnosis Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 71. France SPECT and PET Diagnosis Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 72. UK SPECT and PET Diagnosis Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 73. Italy SPECT and PET Diagnosis Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 74. Russia SPECT and PET Diagnosis Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 75. Middle East & Africa SPECT and PET Diagnosis Radiopharmaceuticals Sales Market Share by Country (2021-2026)
Figure 76. Middle East & Africa SPECT and PET Diagnosis Radiopharmaceuticals Sales Market Share by Type (2021-2026)
Figure 77. Middle East & Africa SPECT and PET Diagnosis Radiopharmaceuticals Sales Market Share by Application (2021-2026)
Figure 78. Egypt SPECT and PET Diagnosis Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 79. South Africa SPECT and PET Diagnosis Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 80. Israel SPECT and PET Diagnosis Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 81. Turkey SPECT and PET Diagnosis Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 82. GCC Countries SPECT and PET Diagnosis Radiopharmaceuticals Revenue Growth 2021-2026 ($ millions)
Figure 83. Manufacturing Cost Structure Analysis of SPECT and PET Diagnosis Radiopharmaceuticals in 2026
Figure 84. Manufacturing Process Analysis of SPECT and PET Diagnosis Radiopharmaceuticals
Figure 85. Industry Chain Structure of SPECT and PET Diagnosis Radiopharmaceuticals
Figure 86. Channels of Distribution
Figure 87. Global SPECT and PET Diagnosis Radiopharmaceuticals Sales Market Forecast by Region (2027-2032)
Figure 88. Global SPECT and PET Diagnosis Radiopharmaceuticals Revenue Market Share Forecast by Region (2027-2032)
Figure 89. Global SPECT and PET Diagnosis Radiopharmaceuticals Sales Market Share Forecast by Type (2027-2032)
Figure 90. Global SPECT and PET Diagnosis Radiopharmaceuticals Revenue Market Share Forecast by Type (2027-2032)
Figure 91. Global SPECT and PET Diagnosis Radiopharmaceuticals Sales Market Share Forecast by Application (2027-2032)
Figure 92. Global SPECT and PET Diagnosis Radiopharmaceuticals Revenue Market Share Forecast by Application (2027-2032)
